1153 related articles for article (PubMed ID: 26775620)
1. BRCAness revisited.
Lord CJ; Ashworth A
Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
[TBL] [Abstract][Full Text] [Related]
3. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
4. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
6. Olaparib for the treatment of breast cancer.
Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
[TBL] [Abstract][Full Text] [Related]
7. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Stok C; Kok YP; van den Tempel N; van Vugt MATM
Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
9. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
11. Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
Copur MS; Gauchan D; Brussow K; Clark D; Ramaekers R
J Clin Oncol; 2015 Aug; 33(23):2582. PubMed ID: 26124479
[No Abstract] [Full Text] [Related]
12. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
13. Defining and Modulating 'BRCAness'.
Byrum AK; Vindigni A; Mosammaparast N
Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
15. Loss of MED12 activates the TGFβ pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells.
Jackson LM; Dhoonmoon A; Hale A; Dennis KA; Schleicher EM; Nicolae CM; Moldovan GL
Nucleic Acids Res; 2021 Dec; 49(22):12855-12869. PubMed ID: 34871431
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme H; Gulati A; Brough R; Fleuren EDG; Bajrami I; Campbell J; Chong IY; Costa-Cabral S; Elliott R; Fenton T; Frankum J; Jones SE; Menon M; Miller R; Pemberton HN; Postel-Vinay S; Rafiq R; Selfe JL; von Kriegsheim A; Munoz AG; Rodriguez J; Shipley J; van der Graaf WTA; Williamson CT; Ryan CJ; Pettitt S; Ashworth A; Strauss SJ; Lord CJ
Sci Rep; 2018 Jul; 8(1):10614. PubMed ID: 30006631
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors plough on.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356598
[No Abstract] [Full Text] [Related]
18. Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
Venkitaraman AR
Cancer Cell; 2009 Aug; 16(2):89-90. PubMed ID: 19647219
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of PARP inhibitor sensitivity.
Turner NC; Ashworth A
Breast Cancer Res Treat; 2011 May; 127(1):283-6. PubMed ID: 21301956
[No Abstract] [Full Text] [Related]
[Next] [New Search]